Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
RESEARCH TOOLSreports
DNLI Analyst Ratings
Strong Buy
16 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
DNLI Stock 12 Month Forecast
Average Price Target
$37.86
▲(126.84% Upside)
| Highest Price Target$80.00 | Average Price Target$37.86 | Lowest Price Target$24.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
Reiterated
03/07/25
Morgan Stanley
Initiated
03/06/25
William Blair
Reiterated
03/06/25
B.Riley Financial
Reiterated
03/05/25
Leerink Partners
Reiterated
03/03/25
Oppenheimer
Reiterated
03/03/25
BTIG
Reiterated
03/02/25
Wedbush
Reiterated
02/28/25
Stifel Nicolaus
Reiterated
02/28/25
H.C. Wainwright
Reiterated
02/27/25
TD Cowen
―
Buy
―
Reiterated
02/27/25
TD Cowen Keeps Their Buy Rating on Denali Therapeutics (DNLI)We expect the drug should be approved with a broad label (see our note her e), which would include both neuronopathic & non-neuronopathic patients, with anticipated US launch in late 2025 or early 2026. This follows positive long-term Ph2 data w/ DNL310 demonstrating clear evidence that Denali's ETVs are able to penetrate the blood-brain barrier and improve cognitive function. Management confirmed the totality of data needed for the filing is complete (though ongoing global Ph2/3 COMPASS should help support full global approval over time). MPS Positive POC Data With Sufficient Follow-Up Should Clear The Way With FDA in MPS IIIa patients is ongoing, and we expect positive POC data from MPS II studies should provide some readthrough to MPS IIIa given their similar mechanisms of action and symptomatic manifestations.
Deutsche Bank
$31
Buy
85.74%
Upside
Initiated
02/11/25
Denali Therapeutics initiated with a Buy at Deutsche BankDenali Therapeutics initiated with a Buy at Deutsche Bank
Goldman Sachs
$45→$40
Buy
139.66%
Upside
Reiterated
01/28/25
Denali Therapeutics Inc. (DNLI) PT Lowered to $40 at Goldman SachsGoldman Sachs analyst Salveen Richter lowered the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $40.00 (from $45.00) while maintaining a Buy rating.
J.P. Morgan
$28→$24
Buy
43.80%
Upside
Reiterated
01/07/25
Denali Therapeutics (DNLI) Gets a Buy from J.P. Morgan
Jefferies
$45
Buy
169.62%
Upside
Assigned
01/07/25
Analysts Offer Insights on Healthcare Companies: Exact Sciences (NASDAQ: EXAS), Denali Therapeutics (NASDAQ: DNLI) and Inspire Medical Systems (NYSE: INSP)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
Reiterated
03/07/25
Morgan Stanley
Initiated
03/06/25
William Blair
Reiterated
03/06/25
B.Riley Financial
Reiterated
03/05/25
Leerink Partners
Reiterated
03/03/25
Oppenheimer
Reiterated
03/03/25
BTIG
Reiterated
03/02/25
Wedbush
Reiterated
02/28/25
Stifel Nicolaus
Reiterated
02/28/25
H.C. Wainwright
Reiterated
02/27/25
TD Cowen
―
Buy
―
Reiterated
02/27/25
TD Cowen Keeps Their Buy Rating on Denali Therapeutics (DNLI)We expect the drug should be approved with a broad label (see our note her e), which would include both neuronopathic & non-neuronopathic patients, with anticipated US launch in late 2025 or early 2026. This follows positive long-term Ph2 data w/ DNL310 demonstrating clear evidence that Denali's ETVs are able to penetrate the blood-brain barrier and improve cognitive function. Management confirmed the totality of data needed for the filing is complete (though ongoing global Ph2/3 COMPASS should help support full global approval over time). MPS Positive POC Data With Sufficient Follow-Up Should Clear The Way With FDA in MPS IIIa patients is ongoing, and we expect positive POC data from MPS II studies should provide some readthrough to MPS IIIa given their similar mechanisms of action and symptomatic manifestations.
Deutsche Bank
$31
Buy
85.74%
Upside
Initiated
02/11/25
Denali Therapeutics initiated with a Buy at Deutsche BankDenali Therapeutics initiated with a Buy at Deutsche Bank
Goldman Sachs
$45→$40
Buy
139.66%
Upside
Reiterated
01/28/25
Denali Therapeutics Inc. (DNLI) PT Lowered to $40 at Goldman SachsGoldman Sachs analyst Salveen Richter lowered the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $40.00 (from $45.00) while maintaining a Buy rating.
J.P. Morgan
$28→$24
Buy
43.80%
Upside
Reiterated
01/07/25
Denali Therapeutics (DNLI) Gets a Buy from J.P. Morgan
Jefferies
$45
Buy
169.62%
Upside
Assigned
01/07/25
Analysts Offer Insights on Healthcare Companies: Exact Sciences (NASDAQ: EXAS), Denali Therapeutics (NASDAQ: DNLI) and Inspire Medical Systems (NYSE: INSP)
Best Analysts Covering Denali Therapeutics
Which Analyst Should I Follow If I Want to Buy DNLI and Sell After:
1 Month
xxx
Success Rate
10/13 ratings generated profit
Average Return
+8.12%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 76.92% of your transactions generating a profit, with an average return of +8.12% per trade.
3 Months
xxx
Success Rate
10/15 ratings generated profit
Average Return
+17.49%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +17.49% per trade.
1 Year
Success Rate
7/15 ratings generated profit
Average Return
+17.91%
reiterated a buy rating 11 days ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +17.91% per trade.
2 Years
xxx
Success Rate
3/11 ratings generated profit
Average Return
-16.55%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 27.27% of your transactions generating a profit, with an average return of -16.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
DNLI Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
7
5
15
16
20
Buy
12
8
10
7
8
Hold
4
3
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
16
26
23
28
Each month's total comprises the sum of three months' worth of ratings.
DNLI Financial Forecast
DNLI Stock Forecast FAQ
What is DNLI’s average 12-month price target, according to analysts?
Based on analyst ratings, Denali Therapeutics’s 12-month average price target is $37.86.
What is DNLI’s upside potential, based on the analysts’ average price target?
Denali Therapeutics has 126.84% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is DNLI a Buy, Sell or Hold?
Denali Therapeutics has a consensus rating of Strong Buy which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.
What is Denali Therapeutics’s price target?
The average price target for Denali Therapeutics is $37.86. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $24.00. The average price target represents 126.84% Increase from the current price of $16.69.
The highest analyst price target is $80.00 ,the lowest forecast is $24.00. The average price target represents 126.84% Increase from the current price of $16.69.
What do analysts say about Denali Therapeutics?
Denali Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of DNLI?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.